LINROLUX Trademark

Trademark Overview


On Monday, February 7, 2022, a trademark application was filed for LINROLUX with the United States Patent and Trademark Office. The USPTO has given the LINROLUX trademark a serial number of 97255961. The federal status of this trademark filing is THIRD EXTENSION - GRANTED as of Thursday, November 7, 2024. This trademark is owned by Bristol-Myers Squibb Company. The LINROLUX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Phar...
linrolux

General Information


Serial Number97255961
Word MarkLINROLUX
Filing DateMonday, February 7, 2022
Status732 - THIRD EXTENSION - GRANTED
Status DateThursday, November 7, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, April 4, 2023

Trademark Statements


Goods and ServicesPharmaceutical preparations for human use for the treatment and prevention of obesity, incontinence, cardiovascular diseases, central nervous system diseases and disorders, metabolic disorders, stroke, cancer, inflammation and inflammatory diseases, respiratory and infectious diseases, auto-immune diseases, solid organ transplant rejection, beta thalassemia and myelodysplastic syndromes, myeloproliferative diseases, myelofibrosis, leukemia, lymphoma, multiple myeloma, autoinflammatory disease, blood disease, tumors, multiple sclerosis, ulcerative colitis, arthritis, and musculoskeletal and skin diseases; Pharmaceutical preparations for human use, namely, antibiotics, anti-fungals, anti-virals, immunosuppressants, pharmaceutical antibodies, immunotherapies for the treatment of cancer, cytokine inhibitory drugs; Pharmaceutical preparations for human use that modulate the immune system; Pharmaceutical and biological preparations for human use for immunotherapy, namely T Cell therapy; Pharmaceutical preparations for human use, namely, stem cells for medical or clinical use; Pharmaceutical preparations for human use for the treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, antivirals for treatment or prevention of covid-19, coronavirus disease, and respiratory diseases and disorders; Pharmaceutical preparations for human use, namely, monoclonal antibodies for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, February 11, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameBristol-Myers Squibb Company
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressPrinceton, NJ 08543

Party NameBristol-Myers Squibb Company
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew York, NY 10016

Trademark Events


Event DateEvent Description
Thursday, February 10, 2022NEW APPLICATION ENTERED
Friday, February 11, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, August 24, 2022ASSIGNED TO EXAMINER
Friday, August 26, 2022NON-FINAL ACTION WRITTEN
Friday, August 26, 2022NON-FINAL ACTION E-MAILED
Friday, August 26, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, February 27, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 27, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 28, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, March 1, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, March 15, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, April 4, 2023PUBLISHED FOR OPPOSITION
Tuesday, April 4, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, May 30, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, August 2, 2023TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, August 2, 2023APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, August 2, 2023TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, November 21, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, November 21, 2023SOU EXTENSION 1 FILED
Tuesday, November 21, 2023SOU EXTENSION 1 GRANTED
Thursday, November 23, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, April 5, 2024SOU TEAS EXTENSION RECEIVED
Friday, April 5, 2024SOU EXTENSION 2 FILED
Friday, April 5, 2024SOU EXTENSION 2 GRANTED
Saturday, April 6, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 7, 2024SOU TEAS EXTENSION RECEIVED
Thursday, November 7, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 7, 2024SOU EXTENSION 3 FILED
Thursday, November 7, 2024SOU EXTENSION 3 GRANTED